Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -6.05% is 96% above its 2-year average of -151.76%, near the high end of its 2-year range (-708.00%–2.50%).
As of the fiscal period ended Tuesday, June 30, 2026. 96.16% above its 12-month average of -157.34%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -6.05%.
RETURN ON EQUITY (ROE)
-6.05%
RETURN ON EQUITY (ROE) AVG TTM
-157.34%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+96.16%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+85.60%
vs the sector median at left
vTv Therapeutics Inc.
Market Cap
$78.59M
Return on Equity (ROE)
-6.05%
TTM Avg
-157.34%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.29M
Return on Equity (ROE)
-55.97%
TTM Avg
-55.58%
3Y Avg
-51.87%
5Y Avg
-151.31%
Market Cap
$79.03M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$78.07M
Return on Equity (ROE)
-1542.57%
TTM Avg
-254.55%
3Y Avg
-187.52%
5Y Avg
-143.69%
Market Cap
$79.61M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$77.54M
Return on Equity (ROE)
N/A
TTM Avg
354.96%
3Y Avg
354.96%
5Y Avg
354.96%
Market Cap
$80.30M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$76.74M
Return on Equity (ROE)
-77.12%
TTM Avg
-270.75%
3Y Avg
-187.09%
5Y Avg
-136.77%
Market Cap
$81.20M
Return on Equity (ROE)
-130.67%
TTM Avg
-143.13%
3Y Avg
-106.90%
5Y Avg
-90.63%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | $78.59M | -6.05% | -157.34% | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -55.97% | -55.58% | -51.87% | -151.31% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | -114.06% | -50.52% | -45.18% | -45.18% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -1542.57% | -254.55% | -187.52% | -143.69% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -85.65% | -57.41% | -45.73% | -8.61% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | 354.96% | 354.96% | 354.96% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -309.44% | -515.53% | -464.77% | -329.14% |
| Outset Medical, Inc. (OM)vs › | $76.74M | -77.12% | -270.75% | -187.09% | -136.77% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -130.67% | -143.13% | -106.90% | -90.63% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -28.85% | -24.95% | -20.92% | -19.20% |
ROE
-6.0%
ROA
-5.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -6.05% |
| 2026-03-31 | 2.50% |
| 2025-12-31 | -41.86% |
| 2025-09-30 | -33.27% |
| 2025-06-30 | -708.00% |
| 2025-03-31 | -235.97% |
| 2024-12-31 | -151.34% |
| 2024-09-30 | -121.97% |
| 2024-06-30 | -122.47% |
| 2024-03-31 | -99.13% |
